Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Icotinib |
| Trade Name | |
| Synonyms | BPI-2009|BPI-2009H|Conmana |
| Drug Descriptions |
Icotinib (BPI-2009) is a selective EGFR inhibitor that inhibits both wild-type and mutant forms of EGFR, which may result in decreased tumor cell proliferation (PMID: 22112293). |
| DrugClasses | EGFR Inhibitor 1st gen 3 |
| CAS Registry Number | 610798-31-7 |
| NCIT ID | C138996 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Icotinib | Bevacizumab Icotinib | 0 | 0 |
| Brigatinib + Cetuximab + Icotinib | Brigatinib Cetuximab Icotinib | 0 | 0 |
| Carboplatin + Icotinib + Pemetrexed Disodium | Carboplatin Icotinib Pemetrexed Disodium | 0 | 0 |
| Crizotinib + Icotinib | Crizotinib Icotinib | 0 | 0 |
| Icotinib | Icotinib | 0 | 1 |
| Icotinib + Osimertinib | Icotinib Osimertinib | 0 | 0 |
| Icotinib + Radiotherapy | Icotinib Radiotherapy | 0 | 0 |
| Icotinib + Rivoceranib | Icotinib Rivoceranib | 0 | 0 |